216 related articles for article (PubMed ID: 9266440)
1. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing.
Forsyth PA; Balmaceda C; Peterson K; Seidman AD; Brasher P; DeAngelis LM
J Neurooncol; 1997 Oct; 35(1):47-53. PubMed ID: 9266440
[TBL] [Abstract][Full Text] [Related]
2. Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings.
Augusto C; Pietro M; Cinzia M; Sergio C; Sara C; Luca G; Scaioli V
J Neurooncol; 2008 Jan; 86(1):89-99. PubMed ID: 17611715
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
4. Reversible peripheral neuropathy induced by a single administration of high-dose paclitaxel.
Iñiguez C; Larrodé P; Mayordomo JI; González P; Adelantado S; Yubero A; Trés A; Morales F
Neurology; 1998 Sep; 51(3):868-70. PubMed ID: 9748043
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy.
Jennaro TS; Fang F; Kidwell KM; Smith EML; Vangipuram K; Burness ML; Griggs JJ; Van Poznak C; Hayes DF; Henry NL; Hertz DL
Breast Cancer Res Treat; 2020 Apr; 180(3):707-714. PubMed ID: 32166478
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.
Reddy SM; Vergo MT; Paice JA; Kwon N; Helenowski IB; Benson AB; Mulcahy MF; Nimeiri HS; Harden RN
Clin Colorectal Cancer; 2016 Mar; 15(1):37-46. PubMed ID: 26337211
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel-induced neuropathy.
Postma TJ; Vermorken JB; Liefting AJ; Pinedo HM; Heimans JJ
Ann Oncol; 1995 May; 6(5):489-94. PubMed ID: 7669713
[TBL] [Abstract][Full Text] [Related]
8. Peripheral neurotoxicity induced by docetaxel.
Hilkens PH; Verweij J; Stoter G; Vecht CJ; van Putten WL; van den Bent MJ
Neurology; 1996 Jan; 46(1):104-8. PubMed ID: 8559354
[TBL] [Abstract][Full Text] [Related]
9. Peripheral neuropathy secondary to docetaxel (Taxotere).
New PZ; Jackson CE; Rinaldi D; Burris H; Barohn RJ
Neurology; 1996 Jan; 46(1):108-11. PubMed ID: 8559355
[TBL] [Abstract][Full Text] [Related]
10. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
Kuroi K; Shimozuma K; Ohashi Y; Hisamatsu K; Masuda N; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Hausheer FH
Support Care Cancer; 2009 Aug; 17(8):1071-80. PubMed ID: 19089463
[TBL] [Abstract][Full Text] [Related]
11. Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy.
Sánchez-Barroso L; Apellaniz-Ruiz M; Gutiérrez-Gutiérrez G; Santos M; Roldán-Romero JM; Curras M; Remacha L; Calsina B; Calvo I; Sereno M; Merino M; García-Donas J; Castelo B; Guerra E; Letón R; Montero-Conde C; Cascón A; Inglada-Pérez L; Robledo M; Rodríguez-Antona C
Oncologist; 2019 Aug; 24(8):e784-e792. PubMed ID: 30470691
[TBL] [Abstract][Full Text] [Related]
12. Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue?
Pace A; Nisticò C; Cuppone F; Bria E; Galiè E; Graziano G; Natoli G; Sperduti I; Jandolo B; Calabretta F; Tomao S; Terzoli E
Clin Breast Cancer; 2007 Apr; 7(7):550-4. PubMed ID: 17509163
[TBL] [Abstract][Full Text] [Related]
13. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study.
Stubblefield MD; Vahdat LT; Balmaceda CM; Troxel AB; Hesdorffer CS; Gooch CL
Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):271-6. PubMed ID: 15997923
[TBL] [Abstract][Full Text] [Related]
14. Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial.
Hanai A; Ishiguro H; Sozu T; Tsuda M; Yano I; Nakagawa T; Imai S; Hamabe Y; Toi M; Arai H; Tsuboyama T
J Natl Cancer Inst; 2018 Feb; 110(2):141-148. PubMed ID: 29924336
[TBL] [Abstract][Full Text] [Related]
15. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.
Moore DH; Donnelly J; McGuire WP; Almadrones L; Cella DF; Herzog TJ; Waggoner SE;
J Clin Oncol; 2003 Nov; 21(22):4207-13. PubMed ID: 14615449
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel (Taxol) induces cumulative mild neurotoxicity.
van Gerven JM; Moll JW; van den Bent MJ; Bontenbal M; van der Burg ME; Verweij J; Vecht CJ
Eur J Cancer; 1994; 30A(8):1074-7. PubMed ID: 7654432
[TBL] [Abstract][Full Text] [Related]
17. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial.
Ghoreishi Z; Esfahani A; Djazayeri A; Djalali M; Golestan B; Ayromlou H; Hashemzade S; Asghari Jafarabadi M; Montazeri V; Keshavarz SA; Darabi M
BMC Cancer; 2012 Aug; 12():355. PubMed ID: 22894640
[TBL] [Abstract][Full Text] [Related]
18. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).
Chhibber A; Mefford J; Stahl EA; Pendergrass SA; Baldwin RM; Owzar K; Li M; Winer EP; Hudis CA; Zembutsu H; Kubo M; Nakamura Y; McLeod HL; Ratain MJ; Shulman LN; Ritchie MD; Plenge RM; Witte JS; Kroetz DL
Pharmacogenomics J; 2014 Aug; 14(4):336-42. PubMed ID: 24513692
[TBL] [Abstract][Full Text] [Related]
19. Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine.
Openshaw H; Beamon K; Synold TW; Longmate J; Slatkin NE; Doroshow JH; Forman S; Margolin K; Morgan R; Shibata S; Somlo G
Clin Cancer Res; 2004 Jan; 10(2):461-7. PubMed ID: 14760066
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.
Zhi WI; Chen P; Kwon A; Chen C; Harte SE; Piulson L; Li S; Patil S; Mao JJ; Bao T
Breast Cancer Res Treat; 2019 Dec; 178(3):587-595. PubMed ID: 31456070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
